The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Immunocore; Polaris; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
John Wagstaff
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; LaRoche Posay; Merck; Novartis; Sanofi
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Christopher D. Lao
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore
 
Ivan Marquez-Rodas
Consulting or Advisory Role - Amgen; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Incyte; Merck Serono; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi
Travel, Accommodations, Expenses - Bioncotech; Bristol-Myers Squibb; MSD; Roche
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Pier F. Ferrucci
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Paul Lorigan
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Michael Smylie
Honoraria - Bristol-Myers Squibb; Merck; Novartis Canada Pharmaceuticals Inc; Roche Canada
Consulting or Advisory Role - Merck; Novartis Canada Pharmaceuticals Inc
 
Wim van Dijck
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jasmine I. Rizzo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech